Randomized, Double-Blind, Placebo-Controlled Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2009
At a glance
- Drugs BMS 767778 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 09 Feb 2009 Planned end date changed from 1 Apr 2009 to 1 Nov 2008 as reported by ClinicalTrials.gov.
- 09 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.